Levent Liu | Investigator, Vaccines R&D
National Health Research Institutes Taiwan | Taiwan

Levent Liu, Investigator, Vaccines R&D, National Health Research Institutes Taiwan

Shih-Jen Liu received his BS in pharmacy at 1989 from Kaohsiung Medical College, Taiwan. After 4 years, He got his Master degree in pharmacology from National Cheng-Kung University, Taiwan at 1993. He then finished his Ph.D. degree in life Science from National Defense Medical Center at 1998. He spent 5-years (1998-2003) in a biotechnological company to develop dendritic cells-based immunotherapy. He and his collaborators conducted the first private company-involved phase I clinical trial in Taiwan. He joined Vaccine Research and Development Center of National Health Research Institutes (NHRI) in 2004. He is now an Investigator and CEO of Bioproduction Plant at National Institute of Infectious Diseases and Vaccinology in NHRI, Taiwan. His research interests include discovery of human cytotoxic T lymphocyte (CTL) epitopes to develop therapeutic vaccines and studies of the molecular mechanism of novel adjuvants. He also found that the antigen presentation mechanisms of lipopetides are different according to the lipid moiety. The TLR2 agonist conjugated long peptide could regulate the process of antigen presentation. Currently, he collaborates with his colleagues to develop recombinant lipoprotein platform technologies and applied to the therapeutic HPV vaccine. This approach is promising for eliminating large tumor and reducing the tumor associated immunosuppressive cells number. The technology of therapeutic HPV vaccine has been licensed to a local company in 2016.

His works have received numerous honors. The “Therapeutic HPV Vaccine” was awarded the ninth “National Innovation Award” by the Institute for Biotechnology and Medicine Industry (2013). The recombinant lipoprotein technology was awarded the seventh “National Innovation Award” by the Institute for Biotechnology and Medicine Industry (2010), and “Silver Invention Award” by the Ministry of Economic Affair, Taiwan (2012). He has more than 70 publications and numerous patents. His work has had a tremendous impact on elucidating the vaccinology and immunology of development of therapeutic vaccines to HPV-associated cancers.


Phar-East Day Two @ 11:30

A novel platform technology for vaccine development

A core platform technology for high production of recombinant lipoproteins with built-in immuno-potentiation for novel subunit vaccine development has been established and fully protected by intellectual property. The lipid moiety of recombinant lipoproteins is identical to that of bacterial lipoproteins, which are recognized as a TLR2 agonist with effects on both innate and adaptive immunity. We have successfully demonstrated the feasibility and safety of our core platform technology in meningococcal group B subunit vaccine (MGBvac), dengue subunit vaccine and therapeutic HPV vaccine in model studies. The MGBvac has been approved by Taiwan FDA for Investigational new drug (IND). 

back to speakers